WALTHAM, Mass.--(BUSINESS WIRE)--Artisan Pharma, Inc. today announced that it has launched a Phase 2b clinical trial of its lead product ART-123 for the treatment of DIC in sepsis. The multi-center, double-blind, placebo controlled trial will enroll 800 sepsis patients who are at high risk of having concurrent disseminated intravascular coagulation (DIC), which in sepsis patients may double their risk of death. Clinical sites expected to contribute to the study include those in North America, Europe, Australia, New Zealand, India and Argentina. ART-123 is being developed in Japan by Asahi Kasei Pharma Corporation (“AKP”)(Tokyo, Japan) for the treatment of DIC. Clinical results demonstrated that ART-123 has an advantage over heparin in resolving DIC and suggested that ART-123 has an encouraging benefit on mortality in DIC patients with infections.
